Genmab · 1 month ago
Center for Outcomes Research, Real World Evidence and Epidemiology (CORE) Intern
Genmab is an international biotechnology company dedicated to improving patient lives through innovative antibody therapeutics. The CORE Intern will work on strategy and projects to demonstrate the value of an oncology product approaching launch, gaining exposure to HEOR, RWE, and Medical Affairs teams.
BiotechnologyHealth CareManufacturingMedical
Responsibilities
Conduct literature search/review re: unmet needs, treatment guidelines, impact of treatment on clinical, economic, patient reported outcomes
Lead HEOR research projects providing input on study design, data analysis and results
Develop/Present (power point slides) on research-related topics to an extended or cross-functional team
Assist in preparations for medical planning and launch planning as appropriate
Assist in preparations for early scientific advice as appropriate
Qualification
Required
PhD student who has completed course work towards a PhD degree in Epidemiology, Economics, Public Health, Pharmaceutical Policy or a closely related area
Strong analytical skills with the ability to translate key insights into strategy / tactics
Organized and detail-oriented
Excellent time management, verbal & written communication skills
Proficiency in SAS/R Programming and experience in working with claims and electronic health record datasets
Preferred
Experience in oncology therapeutic area
Experience using AI tools for HEOR analyses
Company
Genmab
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
H1B Sponsorship
Genmab has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (14)
2024 (10)
2023 (6)
2022 (3)
2021 (3)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$11.7BKey Investors
Morgan Stanley Senior FundingGlaxoSmithKlineIndex Ventures
2025-11-18Post Ipo Debt· $6B
2025-09-29Post Ipo Debt· $5.5B
2010-07-01Post Ipo Equity· $134M
Recent News
2026-01-19
2026-01-19
Pharma Letter
2026-01-18
Company data provided by crunchbase